|
Jul 29
|
NLS Pharmaceutics Signs Binding Term Sheet for Merger With Kadimastem; Shares Rise
|
|
Jul 29
|
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
|
|
Jun 25
|
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
|
|
May 28
|
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
|
|
May 24
|
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
|
|
Mar 14
|
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
|
|
Mar 11
|
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
|
|
Jan 12
|
Notice of Deficiency with Nasdaq Continued Listing Requirements
|
|
Dec 29
|
NLS Pharmaceutics CEO Issues Letter to Shareholders
|
|
Dec 4
|
10 Best Debt Free Penny Stocks To Buy Now
|
|
Dec 1
|
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
|
|
Nov 28
|
NLS Pharmaceutics Announces Election of Additional Board Members
|
|
Nov 27
|
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
|
|
Apr 25
|
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
|